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Abstract
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of 
durable clinical responses in patients with various cancer types.1–5 One mechanism by which 
cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its 
ligation to PD-1 on antigen-specific CD8 T-cells (termed adaptive immune resistance).6,7 Here we 
show that pre-existing CD8 T-cells distinctly located at the invasive tumour margin are associated 
with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. 
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We analyzed samples from 46 patients with metastatic melanoma obtained before and during anti-
PD1 therapy (pembrolizumab) using quantitative immunohistochemistry, quantitative multiplex 
immunofluorescence, and next generation sequencing for T-cell receptors (TCR). In serially 
sampled tumours, responding patients showed proliferation of intratumoural CD8+ T-cells that 
directly correlated with radiographic reduction in tumour size. Pre-treatment samples obtained 
from responding patients showed higher numbers of CD8, PD1, and PD-L1 expressing cells at the 
invasive tumour margin and inside tumours, with close proximity between PD-1 and PD-L1, and a 
more clonal TCR repertoire. Using multivariate analysis, we established a predictive model based 
on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 
patients. Our findings indicate that tumour regression following therapeutic PD-1 blockade 
requires pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1 mediated 
adaptive immune resistance.
Recently, we reported sustained tumour regression in 38% of patients in a multi-
institutional, international, phase 1 expansion study evaluating the safety and clinical 
activity of pembrolizumab (formerly MK-3475 and lambrolizumab), a humanized 
monoclonal antibody against PD-1, in patients with advanced melanoma (ClinicalTrials.gov 
number NCT01295827).3,8 PD-L1, known to be expressed by cells in the tumour 
microenvironment, engages PD-1 on T cells and subsequently triggers inhibitory signalling 
downstream of the TCR, blocking effector functions and reducing T-cell killing capacity.6 
PD-L1 can be constitutively expressed on the surface of cancer cells through poorly 
characterized oncogenic signalling pathways,9,10 or alternatively, expressed in response to 
the presence of T cells producing immune-stimulating cytokines such as interferons.7,11,12 
This later process has been termed adaptive immune resistance,6 and represents a 
mechanism by which cancer cells attempt to protect themselves from immune-cell mediated 
killing.
We sought to determine whether pre-existing tumour-associated CD8+ T-cells inhibited by 
PD-1/PD-L1 engagement represent key factors in determining clinical response to PD-1 
blocking therapy. Our study cohort consisted of 46 patients with advanced melanoma treated 
with single agent pembrolizumab between December 2011 and October 2013 at UCLA 
(IRB# 11-003066). Patients underwent tumour biopsies before and during treatment. 
Baseline biopsy samples from 15 additional patients with advanced melanoma enrolled in 
the same pembrolizumab phase I clinical trial at Gustave Roussy in Villejuif-Paris-Sud, 
France (IRB# 11-040) were analysed as a validation cohort (Extended Data Table 1).
We first examined the spatio-temporal dynamics of CD8+ T-cells by performing qualitative 
and quantitative IHC analysis for CD8 expression before and during PD-1 blockade in two 
tumour compartments: the invasive tumour margin (stromal-tumour edge) and inside the 
tumour parenchyma (tumour center).13,14 S100+ expression was used to define the invasive 
margin and tumour center (Extended Data Fig. 1a). Pre-treatment samples obtained from 
patients who experienced a tumour response (Response group, Fig. 1a), showed higher 
CD8+ cell densities at the invasive margin when compared to samples from patients who 
progressed during therapy (Progression group, Fig. 1b). Extended Data Table 2 provides the 
anatomical location of all tumours serially sampled. Serially sampled tumours during 
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treatment exhibited a parallel increase in CD8+ cell density at both the invasive margin and 
tumour center in the Response group (Spearman’s correlation r = 0.71, p<0.001, Fig. 1c,), 
but not in the Progression group (Fig. 1d). Two patients experienced delayed responses (Fig. 
1c, triangles) and showed step-wise accumulation of CD8+ cells, with initial increases 
restricted to the invasive margin, followed by mobilization into the tumour parenchyma 
(Extended Data Fig. 1b).
Releasing the PD-1 immune checkpoint in pre-existing tumour antigen-specific T cells at the 
invasive margin should lead to T cell proliferation, intratumoural infiltration and increased 
effector function. We found a greater increase in CD8+ density from baseline to post-dosing 
biopsy that significantly correlated with a decrease in radiographic tumour size (Extended 
Data Fig. 2a, Spearman’s correlation r = −0.75, p = 0.0002). During treatment, we found an 
increase in cells that were double positive for CD8 and the nuclear proliferation marker 
Ki67 in samples from patients with a tumour response, as well as all sub-phases of mitosis 
based on characteristic chromatin patterns (Fig. 2 and Extended Data Fig. 2b,c). The post-
dosing increase in CD8/Ki67 double positive cells was restricted to the tumor parenchyma. 
We found increased expression of granzyme B, a cytotoxic granule reflective of CD8 
effector function, on CD8+ cells in post-dosing biopsies in the Response group (p < 0.0001; 
Extended Data Fig. 3a,b).
The correlation between T-cell activation/effector function and treatment outcome upon 
release of the PD-1 immune checkpoint may be driven by the production of interferons by 
tumour-infiltrating CD8 cells that induce PD-L1 expression on tumour-resident cells.11,15 
To test this mechanism, we stained baseline and post-dosing biopsies for phospho-STAT1 
(p-STAT1), which is an immediate downstream effector upon interferon-gamma binding to 
its receptor (Extended Data Fig. 3c,d). The Response group was associated with 
significantly higher expression of pSTAT1+ at the invasive margin, localized to the area of 
CD8 infiltrate, before (p=0.002) and during treatment (p < 0.0001), when compared to 
biopsies from the Progression group. In serially sampled tumours from the Response group, 
pSTAT1 expression was also found to be significantly higher during treatment when 
compared to baseline (p = 0.007). These findings prompted us to investigate the association 
between CD8, CD4, PD-1, and PD-L1 positive cell densities at baseline and treatment 
outcome (Fig. 3a). The Response group was associated with significantly higher numbers of 
CD8+, PD-1+, and PD-L1+ cells at both the invasive margin and the tumour center when 
compared to the Progression group (CD8, p<0.0001; PD-1, p=0.0002; PD-L1, p=0.006). 
However, CD4 expression at baseline was not found to correlate with treatment outcome. 
No relationship was found between previous treatment history with ipilimumab (anti-
CTLA4) and pre-anti-PD1 treatment CD8, PD-1, and PD-L1 expression with respect to 
treatment outcome (Extended Data Table 3).
We next determined the relative proximity of PD-1 and PD-L1 as evidence of a physical 
interaction between PD-1+ and PD-L1+ cells, a presumptive requisite for adaptive immune 
resistance. Fig. 3b shows representative examples of chromogenic PD-1 and PD-L1 
expression in serial cut tissue sections as well as multiplexed PD-1xPD-L1 
immunoflourescence in pre-treatment samples according to treatment outcome. Using 
quantitative multiplexed PD-1xPD-L1 immunofluorescence, we found a significant 
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correlation between proximity of PD-1 and PD-L1 and response to therapy (Fig. 3c, 
p=0.005).
We next investigated the relationship between CD8 and PD-L1 using a Spearman’s 
correlation analysis and found the two markers to correlate in both the tumour (Spearman r 
= .598, p<0.001) and the invasive margin (Spearman r = .527, p<0.001). Furthermore, CD8 
and PD-L1 density co-varied with treatment outcome in both the tumour and invasive 
margin (p<0.001 for both, Extended Data Fig. 4a,b). Immunofluorescence multiplexing for 
CD8 and PD-1 corroborated our chromogenic IHC findings that CD8 T cells represented the 
primary cellular source of PD-1 expression (Extended Data Fig. 4c). Using chromogenic 
double staining for SOX-10xPD-L1, we found PD-L1 expression on melanoma cells and 
also on cells morphologically consistent with lymphocytes and macrophages in samples 
obtained during treatment from the Response group (Extended Data Fig. 5a). Principal 
component analysis of samples obtained before treatment showed that CD8, PD-1 and PD-
L1 expression in the tumour (p=0.001) and at the invasive margin significantly correlated 
with treatment outcome (p<0.0001, Extended Data Fig. 5b).
The high density of CD8+ cells at the site of the tumour in the Response group is suggestive 
of a specific immune response to tumour antigens. Therefore, we hypothesized that a more 
restricted TCR sequence usage would reflect a tumour antigen-specific T-cell accumulation 
at the tumour site. Using genomic DNA isolated from pre-treatment samples, we performed 
next generation sequencing to capture all uniquely rearranged, variable TCR beta chain 
regions.16,17 We found that a more restricted TCR beta chain usage, reflecting a T-cell 
population that was less diverse in repertoire and more clonal in nature, significantly 
correlated with clinical response to pembrolizumab treatment (p=0.004, Fig. 3d). The 
clonality read-out was not found to highly correlate with tumour-infiltrating lymphocyte 
(TIL) density (R2 = 0.04, Extended Data Fig. 10). However, biopsies from patients with a 
tumour response showed evidence of an enriched population of T cells with unique 
specificities. In addition, comparison of the TCR clonality at baseline and post-dosing 
biopsies showed that samples from Responders had more than 10 times as many clones 
expand after anti-PD-1 therapy (Extended Data Fig. 6).
To create the best discriminatory model to assess the probability of clinical response to PD-1 
blocking therapies, forward stepwise logistic regression was run on CD8+, CD4+, PD-1+, 
and PD-L1+ cell densities within the tumour and the invasive margin. Results of the 
stepwise procedure, and a logistic regression model, consistently selected the invasive 
margin CD8+ density as the best full predictive parameter (Extended Data Table 4a). The 
next best predictors were tumour CD8+ T cell density, tumour and invasive margin PD-1+ 
density, and tumour and invasive margin PD-L1+ density. Tumour and invasive margin 
CD4+ density were the poorest predictors.
To test this predictive model, we obtained pre-treatment biopsies from 15 patients treated at 
Gustave Roussy and were blinded to treatment outcome. We quantified CD8+ T cell density 
in the invasive margin and utilized our logistic model to calculate a predicted probability of 
response for each patient in the validation cohort (Extended Data Table 4b). Out of the 15 
patients, we accurately predicted 4 out of 5 patients in the true progression group and 9 out 
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of 9 patients in the true response group. There was one false positive prediction and one 
patient predicted to respond who remains in stable disease.
Our studies build upon the evidence that response rates to PD-1 or PD-L1 blocking 
antibodies are higher in patients whose tumours express PD-L1.1,15 Since PD-L1 can be 
either constitutively expressed or induced upon T cell recognition and production of 
interferons,11,15 we hypothesized that response to PD-1 blockade would more tightly co-
variate with the inducible PD-L1 expression in the presence of antigen-specific T cells,7 
termed adaptive immune resistance.6 Indeed, we found interfacing PD-L1 expressing cells in 
tumours and PD-1 positive T-cells in pre-treatment samples of responders. The clinical 
relevance of the relative distribution of PD-L1 expression on cancer cells, myeloid-derived 
cells and activated T cells in tumours, in terms of treatment outcome, remains to be 
elucidated. Our data suggests that PD-L1 may serve as an indirect marker of adaptive 
immune resistance in response to tumour antigen-specific T cell infiltration rather than a 
static constitutive biomarker. Hence, inducing a type-I interferon inflammatory response in 
combination with PD-L1 blockade merits further clinical investigation.11
T cell infiltrates have been found to have predictive value with respect to the natural history 
of primary cancers.13,14,18 We build on this and herein report that the baseline density and 
location of T cells in metastatic melanomas have predictive value in the treatment outcome 
of patients receiving therapies that block the PD-1/PD-L1 axis. Releasing the PD-1 immune 
checkpoint results in clinically relevant antitumour activity when there is a greater density of 
pre-existing tumour antigen-restricted CD8 T cells that are negatively regulated by 
PD-1/PD-L1 interactions.
METHODS
Tumour samples
Tumour biopsies were obtained from a subset of patients enrolled in a phase 1a clinical trial 
that enrolled 411 patients;19 patients were selected for this analysis by having adequate 
tumour biopsy samples and clinical follow up. All patients in the study and validation 
cohorts underwent mandatory biopsy of a metastatic tumour within 30 days of starting 
treatment and one or more optional biopsies at 20–60 days, 60–120 days, or greater than 120 
days after starting aPD-1. Samples were immediately fixed in formalin followed by paraffin 
embedding. Biopsy collection and analyses were approved by UCLA IRBs 11-001918 and 
11-003066. Tumour samples obtained from the initial cohort of 46 patients from UCLA 
were analyzed for immunohistochemical analysis of CD8 (n=46 patients, 45 samples before 
and 31 samples during treatment), CD4 (n=37 patients, 37 samples before and 0 samples 
during treatment), PD-1 (41= patients, 39 samples before and 26 samples during treatment), 
PD-L1 (n=38 patients, 38 samples before and 24 samples during treatment), multiplex 
immunofluorescence for PD-1 and PD-L1 (n=26 patients, 22 samples before treatment, 25 
samples during treatment), multiplex chromogenic staining (n=13 patients, 12 samples 
before and 17 samples during treatment), and T-cell receptor (VBeta) repertoire (n=23 
patients, 23 samples before treatment). The validation cohort included baseline biopsies of 
16 patients from Gustave Roussy.
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Treatment outcome groups
Patients at both sites received single agent pembrolizumab intravenously in one of three 
dosing regimens: 2 mg/kg every 3 weeks (2Q3W), 10 mg/kg every 3 weeks (10Q3W), or 10 
mg/kg every 2 weeks (10Q2W) within a phase 1 clinical trial that enrolled a total of 411 
patients.19 Tumour responses to pembrolizumab were evaluated at 12 and 16 weeks after the 
first infusion, and every 12 weeks thereafter. Treatment outcomes were statistically identical 
between the three dosing regimens. The Response Evaluation Criteria in Solid Tumours 
(RECIST) version 1.1 was used to define objective clinical responses by an independent, 
central, blinded radiographic review. The protocol allowed to proceed beyond initial 
progression at the restaging scans at 3 months and have repeated imaging scans 4 weeks 
later following the immune-related response criteria (irRC).20 Following this protocol-
specified criteria, two patients had evidence of increase in size of target lesions at 12 weeks, 
but met criteria for objective partial response at 36 weeks and were considered within the 
Response group but denoted as having a delayed response.
Immunohistochemical (IHC) staining
Slides were stained with hematoxylin and eosin, S100, CD8, CD4, CD80, Ki67, pSTAT1, 
and granzyme B at the UCLA Anatomic Pathology IHC Laboratory. Immunostaining was 
performed on Leica Bond III autostainers using Leica Bond ancillary reagents and REFINE 
polymer DAB detection system. Antibodies used included rabbit polyclonal S100 (DAKO, 
1/1500 dilution, low pH retrieval), CD8 clone C8/144B (DAKO, 1/100, low pH retrieval), 
rabbit monoclonal pSTAT1 clone D3B7 (Cell Signaling, 1/300 30min, low pH retrieval). 
PD1 and PD-L1 single-label chromogenic and multiplexed immunofluorescence triple 
staining were performed at Merck laboratories. All staining was performed on Dako 
autostainers. Signal in chromogenically labeled slides was visualized with DAB. Signal in 
immunofluorescently labeled slides was visualized with Alexafluor 488 and Alexafluor 594 
TSA kits (Invitrogen), and nuclei were visualized with Prolong Gold Antifade Reagent with 
DAPI (Invitrogen). All stained slides were evaluated in a blinded fashion by one 
dermatopathologist and one investigator trained to identify the features of melanoma. PD-1 
and PD-L1 stained slides were independently evaluated by one pathologist at Merck 
laboratories. Slides were examined for the presence of CD8, CD4, Ki67, PD-1, and PD-L1 
within the tumour parenchyma (tumour) and the connective tissue surrounding the tumour 
(invasive margin).
The anti-PD-L1 antibody clone 22C3 used in the presented IHC studies is a mouse anti-
human PD-L1 IgG1κ generated through murine immunization with a fusion protein 
containing the human extracellular domain of PD-L1 and subsequent hybridoma formation. 
Binding was screened initially using a cell-based ELISA employing stably transfected CHO 
cells expressing human PD-L1 as positive control and parental (non-transfected) CHO cells 
as negative control. Further screening was performed to assess specificity as an IHC reagent 
for use in FFPE sections through correlation of staining prevalence and intensity on FFPE 
cell pellets from melanoma cell lines to patterns of expression observed on aliquots of the 
same cells analyzed for PD-L1 expression by flow cytometry, and for mRNA expression on 
serial sections of the same blocks using the Nanostring platform (Nanostring, Seattle WA). 
Appropriateness of signal distribution in FFPE tissue was confirmed by correlation of IHC 
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signal pattern in tissue with PD-L1 in situ hybridization studies performed on serial sections 
of the same blocks. Attribution of IHC signal to binding of complementarity determining 
regions of the antibody was confirmed by abrogation of signal on preadsorption of the 
antibody with immunogen. Antigen stability in cut slides and within paraffin blocks was 
evaluated through time course studies to determine changes in dynamic range of the assay 
on pre-sectioned slides as well as on fresh cut slides from existing paraffin blocks over 
periods of months.
Sections cut from formalin fixed paraffin embedded (FFPE) blocks were deparaffinized and 
rehydrated with serial passage through changes of xylene and graded ethanols for PD-1 and 
PD-L1 IHC. All slides were subjected to heat induced epitope retrieval in Envision FLEX 
Target Retrieval Solution, High pH (cat K8012, Dako, Carpineteria CA). Endogenous 
peroxidase in tissues was blocked by incubation of slides in 3% hydrogen peroxide solution 
prior to incubation with primary antibody (anti-PD-L1 clone 22C3, Merck Research 
Laboratories, Palo Alto CA or anti-PD-1 clone NAT105, Cell Marque, Rocklin CA) for 60 
minutes. Antigen-antibody binding was visualized via application of the FLEX+ polymer 
system (cat K8012, Dako, Carpineteria CA) and application of 3,3′ diaminobenzidine 
(DAB) chromogen (K4368, Dako). Stained slides were counterstained with hematoxylin and 
coverslipped for review.
Digital image acquisition and analysis
All slides were scanned at an absolute magnification of 200× (resolution of 0.5 μm/pixel). 
An algorithm was designed based on pattern recognition that quantified immune cells within 
S100 positive areas (tumour) and S100 negative areas (invasive margin). Image analysis 
based on RGB (red, green, blue) spectra was used to detect all cells by counterstaining with 
hemotoxylin (blue), and DAB or fast red. The algorithm calculated the density (cells/mm2) 
and % cellularity (% positive cells/all nucleated cells) using Indica Labs Halo platform. For 
the Proximity Analysis slides fluorescently stained for PD-1 (Alexafluor 488, green channel) 
and PD-L1 (Alexafluor 594, red channel) were scanned to generate digital images in which 
the entire tumour region was sampled using 10,000 random disks. Disks containing both 
green and red signal were scored as positive for PD-1/PD-L1 proximity. The total number of 
positive disks was summed to yield a proximity score for each sample. CD8+ expression was 
determined using two read-outs that were independent of each other to account for tumour 
heterogeneity: cell density (number of positive cells/mm2) and percent cellularity (number 
of positive cells/number of nucleated cells). Cell density and percent cellularity correlated 
significantly (R2 = 0.89 in tumour and 0.84 in the invasive margin).
Next Generation Sequencing for T-cell receptor clonality
TCR sequencing and clonality quantification was performed as previously described16,17 
from tumour samples preserved using RNAlater (Qiagen) and stored at −80°C. DNA was 
isolated by mincing followed by extraction utilizing a DNeasy kit (Qiagen). Melanin was 
then removed from visibly pigmented melanoma samples using a PCR Inhibitor Removal kit 
(Zymo Research). TCRβ CDR3 regions were amplified and sequenced using the survey 
ImmunoSeq assay in a multiplexed PCR method using 45 forward primers specific to TCR 
Vβ gene segments and 13 reverse primers specific to TCR Jβ gene segments (Adaptive 
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Biotechnologies, Seattle, WA). Reads of length 87 bp were obtained using the Illumina 
HiSeq System. For each sample, Shannon entropy was calculated on the clonal abundance of 
all productive TCR sequences in the dataset. Shannon entropy was normalized to the range 
[0–1] by dividing Shannon entropy by the logarithm of the number of unique productive 
TCR sequences in the dataset. This normalized entropy value was then inverted (1 − 
normalized entropy) to produce our clonality metric.
PCR template abundance estimation
In order to estimate the average read coverage per input template in our multiplex PCR and 
sequencing approach, we employed a set of approximately 850 unique types of synthetic 
TCR analog, comprising each combination of Vβ and Jβ gene segments.17 These molecules 
were included in each PCR reaction at very low concentration so that most unique types of 
synthetic template were not observed in the sequencing output. Using the known 
concentration of the synthetic template pool, we simulated the relationship between the 
number of observed unique synthetic molecules and the total number of synthetic molecules 
added to reaction (this is very nearly one-to-one at the low concentrations we employed). 
These molecules then allowed us to calculate for each PCR reaction the mean number of 
sequencing reads obtained per molecule of PCR template, and thus to estimate the number 
of rearranged T cell receptors per diploid genome (i.e., level of TIL infiltration) in the input 
material.
Statistical analysis
Demographic, clinical, and immunohistochemical variables were compared between 
responders and progressors using Wilcoxon rank sum tests for ordinal or quantitative 
variables and Fisher’s exact test for categorical variables. Receiver operating characteristic 
(ROC) curves for response vs. progression were constructed to assess the proprognostic 
ability of CD8, PD-1, CD4, and PD-L1 for both tumour and invasive margin measures. The 
area under the ROC curve (AUC) was used to measure model performance and the 
Wilcoxon test was used to assess significance of the AUC results. A logistic regression 
model was constructed using pre-treatment CD 8+ (cells/mm2) versus the outcome of 
clinical response (PR+SD vs PD) using the study cohort. This fixed model was then applied 
to the CD 8+ density measurements in the Gustave Roussy validation cohort to compute 
predicted probabilities of response to treatment. Sensitivity and specificities were calculated. 
Principal components analysis (PCA) was used to decompose the variance for the markers 
(CD8+, PD-1+, PD-L1+, and CD4+ cell densities in cells/mm2) separately in the tumour and 
in the invasive margin. The first principal component accounted for the majority of the 
variability in the four markers 69.6% and 57.1% in the tumour and invasive margin 
respectively. Principal component scores for the first principal component were compared 
between response groups with Wilcoxon rank sum tests. Analyses were performed using 
GraphPad Prism, SAS, and SPSS. All tests were 2-sided and equal variance was not 
assumed unless otherwise stated. P-values <0.05 were considered statistically significant.
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Extended Data
Extended Data Figure 1. CD8 cell infiltrates in tumor biopsies
a, Segmentation of the invasive margin and tumour parenchyma using S100 and CD8 
chromogenic staining. Low magnification (top row) and high magnification (bottom row) 
are shown. The red dotted line illustrates S100+ tumour (left of red line) and S100− stroma 
(right of red line). Coordinates of the invasive margin and tumour parenchyma are generated 
from the S100 stained image (column labeled S100) and subsequently imported into the 
CD8 stained image (column labeled CD8). This is followed by a deconvolution imaging 
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algorithm of the CD8 stained image where first, all nuclei (column labeled Nuclei+) are 
identified and quantified, irrespective of what type of cell. This is followed by identifying 
CD8+ membrane (column labeled CD8+) for cell quantification and analysis. b, CD8+ T-
cell kinetics within the tumour microenvironment in a serially sampled tumour responding 
to PD-1 blocking therapy. Example of radiographic, clinical, and CD8 IHC in a serially 
sampled melanoma tumour of the left chest wall that was obtained from a patient with a 
delayed response. On day +20, clinical and radiographic examinations indicated progressive 
disease; at a time when CD8 T-cells expression increased in density at the invasive margin.
Extended Data Figure 2. Proliferation of CD8+ T cells in regressing tumours
a, Relationship of the change in CD8+ cell density and best percent change in tumour size in 
serially sampled tumours that were assessed using quantitative immunohistochemistry and 
CT scan measurements (n=18, Spearman r = −0.75, P = 0.0002). b, CD8+ cell density and 
Ki67+/CD8+ cell density in the Response group before treatment (n=11, empty circles) and 
during treatment (n=17, filled circles) and the Progression group before treatment (n=9, 
empty triangles), and during treatment (n=15, filled triangles). c. Representative examples of 
CD8/Ki67 chromogenic double staining from a biopsy of a patient with a tumor response 
and another with progression. Double positive CD8 cells (red labeled Ki67 nucleus, CD8 
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brown labeled membrane) are not present at baseline, but are present during tumor 
regression in the biopsy from a patient with a tumor response. The double positive cells are 
not in the biopsy of a patient with progression during treatment (no Ki-67 labeling in brown 
CD8 cells). Magnification, X40.
Extended Data Figure 3. Granzyme B and pSTAT1 expression before and during treatment in 
terms of clinical response
a, Representative examples of granzyme B expression according to clinical response. b, 
Samples collected during PD-1 blocking therapy were evaluated for granzyme B signal 
(Response n=13, Progression n=12) using quantitative immunohistochemistry. ****P < 
0.0001. c, Representative example of the proximity between CD8+, PD-1+, PD-L1+, and 
pSTAT1+ cells in the tumour microenvironment in a sample obtained before treatment from 
the Response group. Magnification, X40. 2 μM serial cut tissue sections were stained for 
CD8, PD-1, PD-L1, and pSTAT1. d, Localization of CD8+ and pSTAT1+ cells in samples 
obtained before treatment from a biopsy in a patient with response and two patients with 
progression on anti-PD-1 therapy (+/− a CD8 presence). The biopsy from a patient with 
disease progression had a moderate presence of CD8 cells that did not show pSTAT1 
expression in the area. e, Using quantitative IHC analysis, the Response group was 
associated with significantly higher expression of pSTAT1+ at the invasive margin before 
and during treatment (Response n = 16, Progression n = 18, p=0.002 for pre-treatment 
biopsies and Response n = 13, Progression n = 12, p < 0.0001 for post treatment biopsies). 
Within the Response group, pSTAT1 expression was significantly higher during treatment 
when compared to baseline (p = 0.022).
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Extended Data Figure 4. Relationship between CD8 and PD-L1 expression in terms of treatment 
outcome
a, Scatterplots of CD8 and PD-L1 density (cells/mm2) using a log(x+1) scale are shown in 
samples obtained at baseline stratified by treatment outcome. Reference “cut-points” for 
CD8 and PD-L1 densities were based on the median value for each marker across the entire 
cohort. Samples present in the CD8highPD-L1high quadrant, in both tumour and invasive 
margin, were predominantly derived from the Response group. Samples present in the 
CD8lowPD-L1low quadrants were significantly associated with the Progression group 
(Response n=17, Progression n=21, P < 0.001 at both the invasive margin and tumour). b, 
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CD8, PD-1, and PD-L1 expression before treatment in terms of clinical response. 
Representative examples of the proximity between CD8+, PD-1+, PD-L1+ cells in the 
tumour microenvironment in pre-treatment samples obtained from a patient with a tumour 
response and progression. Magnification, X20. 2 μM serial cut tissue sections were stained 
for CD8, PD-1, and PD-L1. c, Multiplexed immunofluorescence staining of CD8 and PD-1 
to evaluate the relative coexpression of CD8 and PD-1 on individual cells within the tumour 
microenvironment. CD8+ cells were were detected using AlexaFluor 488 staining in the 
green channel. PD-1+ cells were detected suing AlexaFluor 594 staining in the red channel. 
High levels of co-expression of the 2 antigens were observed when the two channels are 
combined, yielding yellow signal in areas of colocalization.
Extended Data Figure 5. PD-L1 expression and relationship with T cell infiltration
a, Multiplexed chromogenic staining of SOX-10 (red nucleus) and PD-L1 (brown 
membrane) to evaluate PD-L1 expression on melanoma cells, lymphocytes, and 
macrophages within the tumour microenvironment. SOX-10 is a transcription factor that is 
melanoma cell specific. Representative high power fields of double positive cells (yellow 
arrows) show melanoma cells expressing PD-L1 and single positive PD-L1 cells comprising 
of lymphocytes (high nuclear:cytoplasmic ratio, red arrows) and macrophages (low 
nuclear:cytoplasmic ratio, green arrows) in three responders from samples obtained during 
tumour regression.. Magnification, X40. b, Principal component analysis (PCA) to 
decompose the variance for the markers (CD8+, PD-1+, PD-L1+, and CD4+ cell densities 
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(cells/mm2) separately in the tumour and in the invasive margin. The first principal 
component accounted for the majority of the variability in the four markers 69.6% and 
57.1%, in the tumour center (***P= 0.001) and the invasive margin (****P < 0.0001), 
respectively. Principal component scores for the first principal component were compared 
between response groups with Wilcoxon rank sum tests.
Extended Data Figure 6. Clonality of the T-cell repertoire and density of T-cell infiltration (TIL) 
in terms of clinical response
a, High throughput quantitative sequencing of the rearranged TCR beta genes using the 
ImmunoSeq assay. (Response n=13, Progression n=12). ***P = 0.005 by Fisher’s exact test. 
The x-axis represents clonality of the T cell repertoire (1 – Pielou’s evenness) and the y-axis 
represents the density of tumour-infiltrating T cells (estimated TCR gene rearrangements per 
diploid genomes, see supplementary methods for further detail). The axes cross at the 
median value for clonality and TIL infiltration. TIL infiltration and TIL repertoire clonality 
were found to be independent in this cohort (R2 = 0.04). Progressors were associated with 
lower levels of TIL infiltration and lower TIL clonality (i.e., a more diverse TIL repertoire); 
all patients with below-median clonality and TIL infiltration progressed. b, The uniqueness 
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of the CDR3 TCR sequences enable tracking of clonal expansion or contraction clones in 
serially sampled tumours. Representative scatterplot of clones from a responding tumour 
serially sampled before and during aPD-1 treatment. (1 dot = 1 unique clone: green-
expanded, grey-stable, red-contracted). The x- and y- axes represent the relative abundance 
of each clone before and during treatment, respectively. Clones that met a 2x change in 
frequency from baseline must have also met significance using a Fisher Exact test of the 
clone before and during aPD-1 and the full set of clone reads, followed by Storey’s Qvalue 
for false discovery rate. c, Clonal expansion in terms of clinical response (Response n=6, 
Progression n=5) **P= 0.006
Extended Data Table 1
Demographic and clinical characteristics of patients in the Study and Validation cohorts.
Variable Response Progression p-value*
UCLA Patients (N=46) N=22€ N=24
 Male (%) 17 (74%) 19 (79%) >0.99
 Median Age (range) 65 (45–90) 64 (36–86) 0.86£
 Median WBC Count (range) 6.9 (3.9–21.3) 7.1 (4.0–24.8) 0.52
 Median Pre-TX Tumor Burden in cm (range)¥ 8.7 (1.1–32.2) 7.9 (1.1–19.4) 0.9£
 Metastatic Status
  M0 3 (13%) 2 (8%) 0.13£
  M1a 4 (17%) 2 (8%)
  M1b 7 (30%) 6 (25%)
  M1c 8 (35%) 14 (58%)
 Dosing Regimen
  10Q2W 9 (39%) 5 (21%) 0.2
  10Q3W 8 (35%) 8 (33%)
  2Q3W 5 (22%) 11 (46%)
 BRAF Mutation
  Mutant (# not wild type) 7 (30%) 9 (38%) 0.76
 Previous Treatment
  chemotherapy 3 (13%) 5 (21%) 0.7
  BRAF or MEK inhibitor 3 (13%) 5(21%) 0.7
  immunotherapy
   ipilimumab 8 (35%) 13 (54%) 0.25
   other 7 (30%) 9 (38%) 0.76
 Pre TX Biopsy Location₠
  Subcutaneous 14 (61%) 11 (46%) 0.02£
  Liver 0 8 (33%)
  Lung 5 (22%) 1 (4%)
  Other 3 (13%) 3 (13%)
IGR Patients (N=15) N=10 N=5
 Median Age (range) 55 (26–73) 60 (38–61) 0.77£
 Male (%) 4 (40%) 2 (40%) >0.99
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Variable Response Progression p-value*
 Metastatic Status
  M0 2 (20%) 0 (0%) 0.51£
  M1a 3 (30%) 1 (20%)
  M1b 0 (0%) 1 (20%)
  M1c 5 (50%) 3 (60%)
 Dosing Regimen
  10Q2W 5 (50%) 2 (40%) 0.62
  10Q3W 3 (30%) 3 (60%)
  2Q3W 2 (20%) 0 (0%)
 BRAF Mutation
  Mutant (# not wild type) 4 (40%) 2 (40%) >0.99
 Previous Treatment
  chemotherapy 2 (20%) 3 (60%) 0.25
  BRAF or MEK inhibitor 2 (20%) 0 (0%) 0.52
  immunotherapy
   ipilimumab 4 (40%) 2 (40%) >0.99
   other 1 (10%) 1 (20%) >0.99
Extended Data Table 2
Anatomical location of biopsies performed before and 
during treatment
The anatomical locations that correspond with Figure 1 are provided (Response n=13, 
Progression n=12 tumours biopsied at before and during aPD-1). The term lymph node/
subcutaneous refers to a tumour identified as lymph node on radiographic imaging but with 
no evidence of lymph node architecture on histologic examination. Two out of the 25 
patients had mets in transit which were distinct nodules that were < 1cm apart from each 
other at the time of biopsy.
Patient Baseline Biopsy Post-Dosing Biopsy Anatomical Location Confirmed Overall Response
1 duodenal lesion duodenal lesion Gastrointestinal Response
2 Segment 4 hepatic 
mass
Segment 4 hepatic 
mass
Liver Progression
3 Segment 5 hepatic 
mass
Segment 5 hepatic 
mass
Liver Progression
4 R. lower lobe lung 
mass
R. lower lobe lung 
mass
Lung Response
5 R. lower lobe lung 
mass
R. lower lobe lung 
mass
Lung Response
6 L. axillary mass L. axillary mass Lymph Node (Subcutaneous) Response
7 L. inguinal mass L. inguinal mass Lymph Node (Subcutaneous) Response
8 R. supraclavicular 
fossa mass
R. supraclavicular 
fossa mass
Lymph Node (Subcutaneous) Response
9 R. cervical neck mass R. cervical neck mass Lymph Node (Subcutaneous) Progression
10 R. axillary mass R. axillary mass Lymph Node (Subcutaneous) Progression
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Patient Baseline Biopsy Post-Dosing Biopsy Anatomical Location Confirmed Overall Response
11 R. submandibular mass R. submandibular mass Lymph Node (Subcutaneous) Progression
12 L medial thigh L. medial thigh Subcutaneous/skin Response
13 L. lower back mass L. lower back mass Subcutaneous/skin Response
14 L chest wall mass L. chest wall mass Subcutaneous/skin Response
15 Middle back mass Middle back mass Subcutaneous/skin Response
16 L. face mass L face mass Subcutaneous/skin Response
17 L. scapula mass L scapula mass Subcutaneous/skin Response
18 L. forearm mass L. forearm mass Subcutaneous/skin Progression
19 L popliteal mass L popliteal mass Subcutaneous/skin Progression
20 L. lower abdomen 
mass
L. lower abdomen 
mass
Subcutaneous/skin Progression
21 L lower abdomen mass L. lower abdomen 
mass
Subcutaneous/skin Progression
22 L scalp mass L. scalp mass Subcutaneous/skin Progression
23 L. anterolateral leg 
mass
L. anterolateral leg 
mass
Subcutaneous/skin Progression
24 L. upper arm (mets in 
transit)
L upper arm (mets in 
transit)
Subcutaneous/skin (mets in 
transit)
Response
25 lower leg (mets in 
transit)
lower leg (mets in 
transit)
Subcutaneous/skin (mets in 
transit)
Progression
Extended Data Table 3
CD8, PD-1, PD-L1, CD4 expression, and clonality 
before treatment in terms of clinical response to 
pembrolizumab and previous treatment with 
ipilimumab (anti-CTLA4)
No significant association was found with previous treatment with ipilimumab and 
expression levels of the markers prior to receiving aPD-1 in terms of treatment outcome.
Variable
Ipilimumaub Treatment History
Response (Naïve) vs. 
Response (Treated)
Response (Naïve) vs. 
Progression (All)
Response (Naïve) vs. 
Progression (Treated)
p-value*
Clonality 0.1604 0.0568 0.4213
Tumor density (cells/mm2)
 CD8 0.0513 <0.0001 0.0019
 PD-1 0.1198 0.0028 0.0573
 PD-L1 0.1732 0.0658 0.1645
 CD4 0.2453 0.3453 0.3948
Stroma density (cells/mm2)
 CD8 0.0170 <0.0001 0.0016
 PD-1 0.0358 0.0330 0.1872
 PD-L1 0.3121 0.0049 0.0123
 CD4 0.2051 0.4183 0.4316
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*p-values represent estimations using the non-parametric Mann-Whitney test
Extended Data Table 4
Predictive model and validation
a, ROC curve analysis for clinical response based on pre-treatment CD8+, PD-1+, PD-L1+, 
and CD4+ cells. The area under the ROC curve (AUC) was used to measure response 
prediction performance for pre-treatment CD8+, PD-1+, PD-L1+, and CD4+ cell densities 
(cells/mm2). P-values were computed on the basis of the Wilcoxon rank sum statistic. b, 
Performance of a model for clinical response using CD8+ (cells/mm2). A logistic regression 
model was constructed using pre-treatment CD8+ (cells/mm2) versus the outcome of clinical 
response (PR+SD vs PD) using the study cohort. This fixed model was then applied to the 
CD8+ density measurements in the validation cohort to compute predicted probabilities of 
response to treatment.
a
Variable AUC (95% Cl)* P-value**
Tumour
 CD8+ Density .91 (0.81, 1.00) <0.001
 PD-1+ Density .80 (0.67, 0.94) 0.001
 PD-L1+ Density .71 (0.54, 0.88) 0.026
 CD4+ Density .66 (0.48, 0.84) 0.095
Invasive Margin
 CD8+ Density .94 (0.88, 1.00) <0.001
 PD-1 + Density .80 (0.66, 0.94) 0.001
 PD-L1+ Density .79 (0.64, 0.95) 0.002
 CD4+ Density .66 (0.48, 0.84) 0.095
b
Patient ID
CD8+ Density, 
Before Tx (Invasive 
Margin)
Predicted Probability 
of Response (Logistic 
Model)
Blinded Prediction True Clinical Response (RECIST 1.1)
IGR-A 58 0.35 Progression Progression
IGR-B 159 0.37 Progression Progression
IGR-C 329 0.40 Progression Progression
IGR-D 341 0.41 Progression Progression
IGR-E 2120 0.75 Response Stable
IGR-F 5466 0.98 Response Progression
IGR-G 2211 0.76 Response Response
IGR-H 3810 0.92 Response Response
IGR-I 4294 0.95 Response Response
IGR-J 4948 0.97 Response Response
IGR-K 5565 0.98 Response Response
IGR-L 6004 0.99 Response Response
IGR-M 5951 0.99 Response Complete Response
IGR-N 7230 0.99 Response Complete Response
IGR-O 6320 0.99 Response Complete Response
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Figure 1. Immunohistochemical analysis of CD8+ T cells in samples obtained before and during 
pembrolizumab treatment
a and b, Examples of CD8 expression in melanoma tumours serially biopsied before PD-1 
blocking treatment (Tx) and 20–60 days after treatment began (Days + 20–60) from a patient 
in the Response (a) and Progression (b) groups. Red line separates tumour parenchyma 
(below line) and invasive margin (above line). Magnification, X20. c and d, CD8+ cell 
density at the tumour center and invasive margin in samples from all Responders (c, n = 13) 
and Progressors (d, n = 12) who received a biopsy before and during treatment.● =complete 
response, ○ =partial response, △ = delayed response.
Tumeh et al. Page 21
Nature. Author manuscript; available in PMC 2015 May 26.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Regressing tumours during treatment are associated with proliferating CD8+ T cells 
that localize to the tumour
a, Representative example of CD8/Ki67 chromogenic double staining from a sample 
obtained during tumour regression shows double positive CD8 cells localized to the tumour 
parenchyma. The red line separates the invasive margin (above line) and tumour (below 
line). b, Top: Representative single positive quiescent CD8+ brown cells (no Ki-67 labeling) 
from the invasive margin. Bottom: Representative double positive cells (red labeled Ki67 
nucleus, CD8 brown labeled membrane) with characteristic chromatin patterns associated 
with subphases of mitosis. Magnification, X40.
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Figure 3. Baseline density, location, and proximity of CD8+, PD-1+, PD-L1+, and CD4+ cells, and 
T cell repertoire according to treatment outcome
a, Melanoma samples collected before treatment with PD-1 blocking therapy were assessed 
for CD8 (Response n=22, Progression n=24), PD-1 (Response n=19, Progression n=21), 
PD-L1 (Response n=17, Progression n=21), and CD4 (Response n=19, Progression n=18) 
density by quantitative immunohistochemistry in the tumour compartment and at the 
invasive margin. **P < 0.01, ***P < 0.001, ****P < 0.0001. b, Examples of the relative 
proximity of PD-1 and PD-L1 expressing cells in representative baseline samples from a 
responder and a progressor. c, Proximity analysis of PD-1 and PD-L1 based on multiplex 
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quantitative immunofluorescence in baseline tumour samples (Response n=11, Progression 
n=11). **P = 0.005. d, Results of TCR sequencing performed on 25 whole tumour samples 
taken at baseline (Response n=12, Progression n=11). **P = 0.004. △ = Delayed Response.
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